Melanoma
is the most threatening form of metastatic skin cancer
that develops from melanocytes and causes a large majority of deaths
due to poor therapeutic prognosis. It has significant limitations
in treatment because it shows great resistance to chemotherapy, radiotherapy,
and other therapeutic methods. A noninvasive and clinically accepted
therapeutic modality, photodynamic therapy (PDT), is a promising treatment
option, but it is limitedly applied for melanoma skin cancer treatment.
This is because most of the photosensitizers are unlikely to be expected
to have a remarkable effect on melanoma due to drug efflux by melanin
pigmentation and intrinsic antioxidant defense mechanisms. Moreover,
melanin is a dominant absorber in the spectral region of 500–600
nm that can cause the decreased photoreaction efficiency of photosensitizers.
Herein, to overcome these drawbacks, we have developed a phenylthiourea-conjugated
BODIPY photosensitizer (PTUBDP) for tyrosinase-positive
melanoma-targeted PDT. In light of our results, it exhibited an enhanced
cytotoxic efficacy compared to BDP, a parallel PDT agent that absence
of phenylthiourea unit. PTUBDP shows outstanding effects
of increased oxidative stress by an enhanced cellular uptake of the
tyrosinase positive melanoma cell line (B16F10). This work presents
increased therapeutic efficacy through the combined therapeutic approach,
enabling enhanced reactive oxygen species (ROS) generation as well
as overcoming the critical limitations of melanoma.